TipRanks
Advertisement
Advertisement

TNYA Stock Latest News

Tenaya Therapeutics granted RMAT designation from FDA for TN-401
The FlyTenaya Therapeutics granted RMAT designation from FDA for TN-401
18d ago
TNYA
Analyst Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target Amid Pipeline Progress and Extended Cash Runway
PremiumRatings
Analyst Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target Amid Pipeline Progress and Extended Cash Runway
2M ago
TNYA
Sami Corwin Reiterates Buy on Tenaya, Citing Strong Progress in Lead Gene Therapies and Emerging Upside from TN-301
PremiumRatings
Sami Corwin Reiterates Buy on Tenaya, Citing Strong Progress in Lead Gene Therapies and Emerging Upside from TN-301
2M ago
TNYA
Tenaya Therapeutics reports Q2 EPS (20c), consensus (7c)
PremiumThe Fly
Tenaya Therapeutics reports Q2 EPS (20c), consensus (7c)
2M ago
TNYA
Analyst Reaffirms Buy on Tenaya Therapeutics with Unchanged $4 Price Target Amid Advancing Cardio Gene Therapy Pipeline
PremiumRatings
Analyst Reaffirms Buy on Tenaya Therapeutics with Unchanged $4 Price Target Amid Advancing Cardio Gene Therapy Pipeline
2M ago
TNYA
Tenaya Therapeutics Ends Manufacturing Center Lease, Shifts Strategy
PremiumCompany AnnouncementsTenaya Therapeutics Ends Manufacturing Center Lease, Shifts Strategy
3M ago
8K
TNYA
Tenaya Therapeutics Appoints New Chief Financial Officer
Premium
Company Announcements
Tenaya Therapeutics Appoints New Chief Financial Officer
3M ago
8K
TNYA
Tenaya Therapeutics appoints Eric Hyllengren as CFO
Premium
The Fly
Tenaya Therapeutics appoints Eric Hyllengren as CFO
3M ago
TNYA
ZURA
Tenaya Therapeutics management to meet with Piper Sandler
PremiumThe Fly
Tenaya Therapeutics management to meet with Piper Sandler
4M ago
TNYA
Tenaya Therapeutics Shareholders Approve Expanded Equity Incentive Plan
PremiumCompany Announcements
Tenaya Therapeutics Shareholders Approve Expanded Equity Incentive Plan
4M ago
8K
TNYA
Buy Rating Reiterated on Tenaya: Promising TN-401 RIDGE-1 Data, Strong Transgene Expression, and Upcoming Catalysts Support Attractive Risk/Reward
PremiumRatings
Buy Rating Reiterated on Tenaya: Promising TN-401 RIDGE-1 Data, Strong Transgene Expression, and Upcoming Catalysts Support Attractive Risk/Reward
5M ago
TNYA
Tenaya reports data from RIDGE-1 Phase 1b/2 clinical trial of TN-401
PremiumThe Fly
Tenaya reports data from RIDGE-1 Phase 1b/2 clinical trial of TN-401
5M ago
TNYA
Tenaya Therapeutics: Buy Rating Reiterated on Upcoming Gene Therapy Catalysts and Unchanged $5 Price Target
PremiumRatingsTenaya Therapeutics: Buy Rating Reiterated on Upcoming Gene Therapy Catalysts and Unchanged $5 Price Target
5M ago
TNYA
Tenaya Therapeutics reports Q1 EPS (9c), consensus (9c)
Premium
The Fly
Tenaya Therapeutics reports Q1 EPS (9c), consensus (9c)
5M ago
TNYA
Tenaya Therapeutics Duchenne muscular dystrophy treatment granted orphan status
Premium
The Fly
Tenaya Therapeutics Duchenne muscular dystrophy treatment granted orphan status
6M ago
TNYA
Tenaya’s TN-401: Differentiated PKP2 Gene Therapy Opportunity Underpins Favorable Risk–Reward and Buy Rating
PremiumRatings
Tenaya’s TN-401: Differentiated PKP2 Gene Therapy Opportunity Underpins Favorable Risk–Reward and Buy Rating
6M ago
TNYA
Advancing Pipeline and Regulatory Clarity Underpin Buy Rating on Tenaya Therapeutics
PremiumRatings
Advancing Pipeline and Regulatory Clarity Underpin Buy Rating on Tenaya Therapeutics
7M ago
TNYA
Tenaya Therapeutics: Early Gene Therapy Promise, Cash Runway to 2H27, and 2026 Data Catalysts Support Buy Rating and $5 Target
PremiumRatings
Tenaya Therapeutics: Early Gene Therapy Promise, Cash Runway to 2H27, and 2026 Data Catalysts Support Buy Rating and $5 Target
7M ago
TNYA
Tenaya Therapeutics: Gene Therapy Momentum and De‑Risking Clinical Milestones Support Buy Rating
PremiumRatings
Tenaya Therapeutics: Gene Therapy Momentum and De‑Risking Clinical Milestones Support Buy Rating
7M ago
TNYA
Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)
PremiumThe FlyTenaya Therapeutics reports Q4 EPS (12c), consensus (12c)
7M ago
TNYA
3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
7M ago
EVAX
IMRX
TN-301: Differentiated HDAC6 Inhibitor Offering Dual Skeletal and Cardiac Benefit in DMD with Multiple Near-Term Catalysts
Premium
Ratings
TN-301: Differentiated HDAC6 Inhibitor Offering Dual Skeletal and Cardiac Benefit in DMD with Multiple Near-Term Catalysts
7M ago
TNYA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >